FDA Clears New Capabilities for Diabetes App BlueStar

The app-based system can now make insulin dose recommendations based on continuous glucose monitor (CGM) data.
Medscape Medical News

source https://www.medscape.com/viewarticle/995972?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost